NCT01137383View on ClinicalTrials.gov

Pegaferon and Ribavirin for Hepatitis C

PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

February 28, 2010

Conditions
Hepatitis C
Interventions
DRUG

Pegaferon (pegylated interferon alpha 2a) + ribavirin

pegylated interferon 180 micrograms subcutaneously weekly - ribavirin (oral, in two divided daily doses) 800 mg for genotype 2 and 3, 1000 or 1200mg (weight less than or greater than 75kg) for genotypes 1 and 4 - Duration: 24 weeks for genotype 2 and 3, 48 weeks for genotypes 1 and 4

Trial Locations (2)

Unknown

Emam Hospital, Tehran

Shariati Hospital, Tehran

All Listed Sponsors
collaborator

Pars No Tarkib Co

UNKNOWN

lead

Tehran University of Medical Sciences

OTHER

NCT01137383 - Pegaferon and Ribavirin for Hepatitis C | Biotech Hunter | Biotech Hunter